1. What is it?
Melanotan II is a synthetic peptide whose structure resembles a fragment of the hormone that stimulates pigment cells. Its molecule has a closed ring structure. The name is not a shorthand for all tanning products. Nor does it mean a new version of the approved medicine Scenesse. Afamelanotide and Melanotan II need to be considered separately: they differ in structure, research history and the effects and risks documented for each. [133] [130]
2. Why do people turn to it?
Darker skin is the main reason for interest in Melanotan II. Effects on libido, erections and appetite also attract attention. Early studies examined pigmentation and induced erections in men. They do not establish cosmetic use in a broad population or obesity treatment. Reduced appetite or darker skin after a substance does not show whether its expected benefits justify the risks. [133] [134] [135]
3. How does it work?
The substance acts on the melanocortin receptor system. This system is involved in pigment production, regulation of eating and sexual responses, among other functions. Its action therefore extends beyond the skin. Small experiments also observed nausea, yawning and spontaneous erections. Unwanted symptoms do not necessarily indicate an excessively strong tan; they may reflect effects on other parts of the body. This is an important distinction between a change in appearance and effects throughout the body. [133] [134]
4. What do studies actually show?
A phase 1 pilot published in 1996 included only three healthy men. Effects on pigmentation were observed, along with symptoms such as nausea, drowsiness and tiredness. A 1998 study enrolled ten men with erectile dysfunction without a known organic cause. Erections were recorded during a short observation period. Studies this small can identify a substance's activity, but do not provide a reliable assessment of the safety of widespread use. [133] [134]
5. What do we still not know?
These studies do not establish the balance of benefits and risks after months or years. They cannot determine safety in women, people with multiple illnesses or users of different products. Skin darkening is not an assessment of skin-cancer risk either. Individual case reports can warn of a complication, but do not establish its frequency or risk across the population. [133] [134] [135]
6. What are the risks?
A particularly serious reported complication is priapism: a prolonged, abnormal erection that can damage tissue. A 2021 publication described a case requiring surgery after Melanotan II use. A painful erection that lasts a long time requires urgent medical attention. A case report cannot establish how often this happens, but it shows that the risks extend beyond temporary nausea. Short studies also cannot rule out other, rarer complications. [135] [133]
7. Is it an approved medicine?
Melanotan II should not be presented as an approved tanning equivalent of Scenesse. Scenesse's European authorisation concerns afamelanotide and a specific disease, EPP. FDA documents on Melanotan II describe consideration of a bulk substance for compounding medicines, which is not product approval. The sources reviewed do not confirm an approved Melanotan II medicine for cosmetic skin darkening. The mere appearance of a name in an official database does not change that assessment. [129] [136]
8. What is new in research?
The FDA document updated on 22 April 2026 recorded withdrawal of the Melanotan II nominations by their applicants and plans to seek committee advice later. This is neither a positive trial result nor drug approval. As of 3 November 2026, there is no basis for announcing a breakthrough in the safety of tanning with this peptide. Older small trials must still be read alongside complication reports and gaps in long-term data. [136] [133] [135]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study
Phase 1 pilot in three men; 1996; PubMed abstract read. Accessed: 03.11.2026.
- Melanotan Tanning Injection: A Rare Cause of Priapism
Single medical case report; February 2021 journal issue; abstract of the full text in PMC read. Accessed: 03.11.2026.
- Scenesse
Current EMA documentation; page updated 7 October 2026; indication, authorisation status, mechanism and monitoring information reviewed. Accessed: 3 November 2026.
- Scenesse, INN-afamelanotide
EMA product information updated 7 October 2026; indication and sections on contraindications, warnings and side effects reviewed. Accessed: 3 November 2026.
- Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study
Small randomised crossover study in humans; 1998; PubMed abstract read. Accessed: 03.11.2026.
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
FDA document, version dated 22.04.2026; section on withdrawal of the Melanotan II nomination and plans for a future consultation was read; this is not medicine approval. Accessed: 03.11.2026.